Pharma & drug development · Reference
What is a biosimilar?
A biosimilar is a biological medicine that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety or effectiveness. It is called “similar”, not identical, because biologics cannot be copied exactly.
Why “similar” and not “identical”
The distinction between a biosimilar and a generic turns on the nature of the product. Generics are small, chemically synthesised molecules that can be reproduced exactly. Biologics — such as monoclonal antibodies and therapeutic proteins — are large, complex molecules manufactured in living cells, and that biological process introduces inherent variability. Even a manufacturer’s own batches of a reference biologic vary slightly. A biosimilar therefore cannot be an exact duplicate; the regulatory aim is that it be highly similar, with any minor differences shown to be clinically irrelevant. This is a scientific and regulatory concept, not a recommendation about any product.
The regulatory pathway
Biosimilars are approved through a dedicated abbreviated pathway, distinct from the generic ANDA route. Rather than repeating the reference product’s full clinical programme, the developer builds a case from analytical comparison — detailed structural and functional characterisation — supplemented by the clinical studies needed to confirm no clinically meaningful differences. The FDA evaluates this “totality of evidence”. Some biosimilars may additionally be designated interchangeable after meeting further requirements. As with all medicines, the product must be made under Good Manufacturing Practice.
Biosimilars in context
Biosimilars are the biologic analogue of generics: they emerge after the reference biologic’s patents and exclusivity expire, introducing competition for products that were previously single-source. Because developing and characterising a biologic is demanding, the biosimilar pathway is more involved than the generic one, but it still avoids duplicating the original’s full discovery and confirmatory programme.
The category reflects how the pharmaceutical industry has adapted regulation to an era of biologic medicines. This overview explains the concept and pathway at an educational level and does not offer guidance on choosing or switching between specific products.
Key facts
At a glance
- Definition: Highly similar to an approved reference biologic
- Not identical: Biologics cannot be copied exactly
- Basis: Analytical comparison plus confirmatory studies
- Standard: No clinically meaningful differences from reference
- Pathway: Dedicated biosimilar route, not the generic ANDA
- Interchangeable: A further designation some biosimilars meet
Common questions
FAQ
What is a biosimilar?+
A biosimilar is a biological medicine that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety or effectiveness. It is an educational description of a regulatory category, not advice about using any specific medicine.
Why is a biosimilar not called a generic?+
Generics are small molecules that can be reproduced exactly, whereas biologics are large, complex molecules made in living cells and cannot be copied identically. Because an exact copy is not possible, the term “biosimilar” reflects that the product is highly similar rather than identical.
What does “interchangeable” mean for a biosimilar?+
Interchangeable is an additional designation that a biosimilar can earn by meeting further regulatory requirements. It is a regulatory status; this overview does not give guidance on substituting or switching specific products.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
